Last reviewed · How we verify
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants \<2 years of age with invasive fungal infection (IFI).
Details
| Lead sponsor | Merck Sharp & Dohme LLC |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 40 |
| Start date | Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Dec 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Invasive Fungal Infection
Interventions
- Posaconazole IV 6 mg/kg
- Posaconazole PFS 6 mg/kg
Countries
Russia, Greece, Ukraine, Peru, Belgium, Israel, Poland, Mexico, South Korea, United States